About Us

Laser Focus World is an industry bedrock—first published in 1965 and still going strong. We publish original articles about cutting-edge advances in lasers, optics, photonics, sensors, and quantum technologies, as well as test and measurement, and the shift currently underway to usher in the photonic integrated circuits, optical interconnects, and copackaged electronics and photonics to deliver the speed and efficiency essential for data centers of the future.

Our 80,000 qualified print subscribers—and 130,000 12-month engaged online audience—trust us to dive in and provide original journalism you won’t find elsewhere covering key emerging areas such as laser-driven inertial confinement fusion, lasers in space, integrated photonics, chipscale lasers, LiDAR, metasurfaces, high-energy laser weaponry, photonic crystals, and quantum computing/sensors/communications. We cover the innovations driving these markets.

Laser Focus World is part of Endeavor Business Media, a division of EndeavorB2B.

Laser Focus World Membership

Never miss any articles, videos, podcasts, or webinars by signing up for membership access to Laser Focus World online. You can manage your preferences all in one place—and provide our editorial team with your valued feedback.

Magazine Subscription

Can you subscribe to receive our print issue for free? Yes, you sure can!

Newsletter Subscription

A Laser Focus World newsletter subscription is free to qualified professionals:

The Daily Beam

Showcases the newest content from Laser Focus World, including photonics- and optics-based applications, components, research, and trends. (Daily)

Product Watch

The latest in products within the photonics industry. (9x per year)

Bio & Life Sciences Product Watch

The latest in products within the biophotonics industry. (4x per year)

Laser Processing Product Watch

The latest in products within the laser processing industry. (3x per year)

Get Published!

If you’d like to write an article for us, reach out with a short pitch to Sally Cole Johnson: [email protected]. We love to hear from you.

Photonics Hot List

Laser Focus World produces a video newscast that gives a peek into what’s happening in the world of photonics.

Following the Photons: A Photonics Podcast

Following the Photons: A Photonics Podcast dives deep into the fascinating world of photonics. Our weekly episodes feature interviews and discussions with industry and research experts, providing valuable perspectives on the issues, technologies, and trends shaping the photonics community.

Social Media

Bluesky • Facebook • Instagram • LinkedIn • YouTube

Meet the Laser Focus World Team

Editorial

Sales

Editorial Advisory Board

  • Professor Andrea M. Armani, University of Southern California
  • Ruti Ben-Shlomi, Ph.D., LightSolver
  • James Butler, Ph.D., Hamamatsu
  • Natalie Fardian-Melamed, Ph.D., Columbia University
  • Justin Sigley, Ph.D., AmeriCOM
  • Professor Birgit Stiller, Max Planck Institute for the Science of Light, and Leibniz University of Hannover
  • Professor Stephen Sweeney, University of Glasgow
  • Mohan Wang, Ph.D., University of Oxford
  • Professor Xuchen Wang, Harbin Engineering University
  • Professor Stefan Witte, Delft University of Technology
My Watchlist
Indicators
Industrial Laser Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

CareDx Announces Landmark KOAR Study Published in the American Journal of Transplantation

By: via Business Wire

KOAR, the Largest Prospective Study of Its Kind, Demonstrates Clinical Utility of AlloSure® in Kidney Transplant Surveillance

AlloSure Kidney dd-cfDNA Elevation Strongly Predicts Rejection and Improves Biopsy Yield

CareDx, Inc. (Nasdaq: CDNA), — The Transplant Company™ — a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, today announced the publication of the Kidney Allograft Outcomes AlloSure Registry (KOAR) study in the American Journal of Transplantation. The landmark prospective study demonstrates the clinical utility of AlloSure® donor-derived cell-free DNA (dd-cfDNA) in improving rejection detection and guiding biopsy decisions in kidney transplant recipients.

The KOAR study enrolled 1,743 patients across 56 U.S. transplant centers to evaluate the clinical utility of a dd-cfDNA surveillance protocol based on the DART study, which prescribed seven tests in year one and four annually in years two and three. A total of 18,584 AlloSure tests were obtained from the overall cohort.

“The scale and clarity of KOAR make it a landmark,” said Daniel C. Brennan, MD, Professor of Medicine at Johns Hopkins, author of the publication, and the senior author of the primary DART publication. “In fact, it shows that dd-cfDNA should be considered the first-line test even before DSA. It’s arguably the most powerful biomarker we have in kidney transplantation today.”

“KOAR confirms that dd-cfDNA is a clinically actionable tool that enhances how we detect and manage rejection,” said Jonathan S. Bromberg, MD, PhD, Professor of Surgery at the University of Maryland, lead author of the publication, and a key author on the DART publications. “Importantly, it helps clinicians tailor care based on risk.”

Key findings include:

  • Elevated AlloSure was associated with a 6-fold increase in rejection yield in surveillance biopsies (39% vs. 7%, p<0.001) and a 4-fold increase in for-cause biopsies (47% vs. 12%, p<0.001).
  • AlloSure elevations were detectable up to four months before ABMR and one month before TCMR, supporting its role in early detection and longitudinal monitoring.
  • In post-biopsy monitoring, AlloSure levels declined significantly following treatment, while serum creatinine remained unchanged, reinforcing AlloSure’s role in assessing treatment response.

The study also demonstrated that dd-cfDNA levels correlate with rejection severity, with higher levels associated with ABMR and mixed rejection, and lower levels linked to borderline or TCMR 1A. This stratification capability positions AlloSure as a critical tool for tailoring immunosuppression and biopsy decisions based on individual patient risk.

“The KOAR study provides compelling evidence that dd-cfDNA can optimize biopsy utilization and improve clinical decision-making in kidney transplant care,” said Robert Woodward, Chief Scientific Officer of CareDx. “AlloSure empowers physicians to detect rejection earlier and intervene more precisely, to achieve the ultimate goal of improving long-term graft survival.”

The full publication is available online at: https://www.amjtransplant.org/article/S1600-6135(25)02875-8/fulltext

About CareDx

CareDx, Inc., headquartered in Brisbane, California, is a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. For more information, visit www.caredx.com.

Forward Looking Statements

This press release includes forward-looking statements related to CareDx, Inc., including statements regarding the potential benefits and results that may be achieved with AlloSure Kidney. These forward-looking statements are based upon information that is currently available to CareDx and its current expectations, speak only as of the date hereof, and are subject to risks and uncertainties that could cause actual results to differ materially from those projected, including risks that CareDx does not realize the expected benefits of AlloSure Kidney; risks that the findings in the KAOR study supporting the data may be inaccurate, general economic and market factors; risks that the findings in the studies supporting the data may be inaccurate, general economic and market factors, and other risks discussed in CareDx’s filings with the Securities and Exchange Commission (the “SEC”), including, but not limited to, the Annual Report on Form 10-K for the fiscal year ended December 31, 2024 filed by CareDx with the SEC on February 28, 2025, and other reports that CareDx has filed with the SEC. Any of these may cause CareDx’s actual results, performance, or achievements to differ materially and adversely from those anticipated or implied by CareDx’s forward-looking statements. You are cautioned not to place undue reliance on these forward-looking statements. CareDx expressly disclaims any obligation, except as required by law, or undertaking to update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise.

Contacts

More News

View More
Bassett Furniture: Buy Now, Sit Back, and Collect Dividends
Via MarketBeat
Tickers BSET ETD HVT
AST SpaceMobile's Big Win: Shares Soar on New Deal With Verizon
Via MarketBeat
Tickers ASTS JOBY RGTI T VOD VZ
Catch the Next Bitcoin Rally With These 3 ETFs
Via MarketBeat
Topics ETFs
Tickers BITQ FBTC IBIT
MarketBeat Week in Review – 10/06 - 10/10
Via MarketBeat
Topics Economy
Tickers ACHR AMD AMZN AVGO CELH CRWV
3 Heavily Shorted Stocks That Could Pop on Rate Cuts
Via MarketBeat
Topics Artificial Intelligence Economy
Tickers ETSY SMR SOUN
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.